Evercore ISI cuts Aflac stock price target on capital concerns By Investing.com

Evercore ISI cut Aflac's price target to $109 from $112 while keeping an Underperform rating, citing excess capital trends and limited apparent capital benefit from the reinsurance deal. Aflac also reported $1 billion of share repurchases and a mixed Q4 2025 print: EPS of $1.57 missed the $1.70 estimate, while revenue of $4.87 billion beat the $4.28 billion consensus. Other analysts remain cautious, with Barclays at Underweight and Mizuho raising its target to $107 but still expecting a negative 6% return.

Analysis

The key read-through is not about the headline number; it is about capital intensity and balance-sheet optionality. When a financial with excess capital is simultaneously increasing buybacks and seeing capital metrics drift lower, the market usually starts discounting a higher future cost of growth or a less forgiving underwriting cycle. That tends to compress multiple expansion even if near-term earnings are supported by reserve releases, because investors will ask whether the buyback pace is sustainable beyond the next two quarters.

The bigger second-order issue is that conservatism in prior reserves can become a double-edged sword: it creates future earnings support, but it also signals that the reported earnings stream may be more sensitive to actuarial assumptions than peers. If Japan benefit ratios stay elevated for another 1-2 quarters, the market will likely shift from treating reserve release as a cushion to treating it as a temporary offset against underlying margin pressure. That is especially relevant in a slowing-rate environment, where insurers often lose the benefit of float reinvestment while claims volatility can stay sticky.

Consensus seems to be anchoring on the idea that capital return will buoy the stock, but that can be overdone if excess capital is already normalizing. The more interesting contrarian setup is that the stock can de-rate even while management continues buying back shares, simply because buybacks are being interpreted as defensive rather than accretive. In that scenario, the best risk/reward is not a directional long on the name itself, but a relative-value short against a higher-quality insurer with steadier capital generation and less accounting noise.

Key Decisions for Investors

• Maintain or initiate a tactical short in AFL for 1-3 months into the actuarial review window; thesis is multiple compression from capital normalization and lower confidence in reserve-release durability. Use a tight stop above the recent buyback-supported highs.
• Pair trade: short AFL / long a higher-quality P&C or diversified insurer with cleaner capital generation and less reserve sensitivity. The trade works if the market starts rewarding earnings quality over capital return optics.
• If expressing upside, use call spreads instead of stock long: 1-2 quarter horizon with limited premium outlay, because the main catalyst is a discrete review rather than a durable re-rating.
• Avoid chasing the buyback headline until the next capital update; if excess capital keeps falling, repurchases become less supportive and the stock can lag even on decent earnings.